Responder analysis for NIS and NIS-LL scores
muscle weakness, Neuropathy
MUSCLE WEAKNESS, NEUROPATHY
Results from the responder analysis for all NIS and NIS-LL scores are shown in Figs. Proportion of Responders at Week 65 by Treatment Arm for NIS Total and Subscale Scores. Abbreviations: CI, confidence interval; NIS, Neuropathy Impairment Score; OR, odds ratioProportion of Responders at Week 65 by Treatment Arm for NIS-LL Total and Subscale Scores. Abbreviations: CI, confidence interval; NIS-LL, Neuropathy Impairment Score – Lower Limb; OR, odds ratioFor each NIS-LL score, the proportion of responders at week 65 was larger among patients receiving inotersen (range: 71–78%) than patients receiving placebo (38–60%). Statistically significant treatment differences in proportion of responders were observed for NIS-LL total (OR = 5.6) and muscle weakness (3.6), 